The Growing Market for Weight Loss Treatments: Innovation, Patents, and the Future of GLP-1 Agonists

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and development efforts. Historically, oncology and immunology were the primary targets for pharmaceutical companies, with most resources and capital allocated to developing new technologies in these areas.

However, the COVID-19 pandemic shifted this dynamic. COVID-19 vaccines became the best-selling pharmaceutical products in both 2021 and 2022. Since 2023, there has been rapid growth in the market for weight loss medications, as well as treatments for obesity and diabetes. This sector has shown considerable increases in global sales, attracting more and more investment from pharmaceutical companies.

The Rise of Glucagon-Like Peptide-1 (GLP-1) Agonists

The rapid expansion of this pharmaceutical sector is largely driven by treatments using GLP-1 agonists. These drugs have been used to treat type 2 diabetes for about two decades and were more recently approved for weight loss. Currently, there are four main treatments propelling this market forward:

• Ozempic and Wegovy (semaglutide: a GLP-1 agonist, developed by Novo Nordisk)
• Mounjaro and Zepbound (tirzepatide: a dual agonist targeting both GLP-1 and GIP (Gastric inhibitory polypeptide) receptors, developed by Eli Lilly)

These medications are administered subcutaneously with the assistance of injection pens. To ensure market exclusivity, Novo Nordisk and Eli Lilly have secured patents for these drugs worldwide. In Brazil, the primary patent for semaglutide is set to expire in 2026, paving the way for the introduction of generic drugs into the Brazilian market.

Competitive Dynamics and Future Developments

With the spotlight on this segment of the pharmaceutical industry, competitors and generic manufacturers are moving quickly to capitalize on this trend. Simultaneously, market leaders continue to improve and develop new treatments for these conditions. For instance, Novo Nordisk is currently testing CagriSema, a combination of semaglutide and cagrilintide, which could further enhance their product portfolio.

This evolving landscape highlights the growing importance of innovation and patent strategies in shaping the future of weight loss and obesity treatments.

Brazil Sees a Surge in Weight Loss Patent Applications

An analysis of data (conducted internally by Daniel) from the Brazilian Patent and Trademark Office (BPTO) reveals two significant peaks in patent application filings related to weight loss technologies: the first occurred between 2006 and 2008, and the second between 2022 and 2024. These trends underscore the ongoing expansion of this technological field.

Eli Lilly and Novo Nordisk stand out as the applicants with the highest number of patent filings at the BPTO. Regarding the origin of the applicants, the majority are based in the United States, followed by South Korea, Denmark, China, and Switzerland.

Since 2022, the presence of new players filing patent applications related to this technology in Brazil has become evident, reflecting the pharmaceutical industry’s rapid response to the growing demand for weight loss and obesity medications.

Obtaining Patent Protection for GLP-1 Inventions

In Brazil, it is possible to obtain patent protection for this type of technology through various embodiments, including compounds; compositions, combinations, or kits containing active ingredients; methods for preparing such compounds; crystalline forms of a compound; and the therapeutic uses of these compounds for treating diseases.

Below are examples of claims eligible for patent protection in Brazil in this context:

The protection of such technology through patents is of paramount importance, especially in the case of high-value-added pharmaceutical products. Patents not only safeguard the significant investments made in research and development but also provide the necessary exclusivity to incentivize innovation and ensure a return on investment.

Patents Play a Crucial Role

The rapid evolution of the pharmaceutical industry, particularly in the growing weight loss and diabetes and obesity treatment market, underscores the critical role of innovation and the need for well-developed patent strategies. In the pharmaceutical sector, where the development process is lengthy, costly, and subject to rigorous regulatory approval, patents play a crucial role in protecting groundbreaking advancements. In Brazil, the patent system provides a vital framework for protecting these technologies, fostering a competitive yet innovation-driven environment.

Image Source: Deposit Photos
Author: mesiluk
Image ID: 745476024